Skip to main content
. 2012 Aug 10;75(4):979–989. doi: 10.1111/j.1365-2125.2012.04416.x

Figure 2.

Figure 2

Range of heart rate observations during the pre-therapy period and placebo and exenatide treatment. The range of observed heart rates at pre-therapy (A) and on placebo (B) treatment overlapped with the range observed on exenatide (C). Inline graphic, pre-therapy (Day −1); Inline graphic, placebo; Inline graphic, 200 pg ml−1 target exenatide concentration (Day 1); Inline graphic, 300 pg ml−1 target exenatide concentration (Day 2); Inline graphic, 500 pg ml−1 target exenatide concentration (Day 3)